Scinai Immunotherapeutics Ltd ADR (SCNI)

$1.01 +0.02 (2.02%)
Market Cap 3.12M
Revenue (ttm) 660,000.00
Net Income (ttm) 4.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 727.27%
Debt to Equity Ratio 0.04
Volume 40,100
Avg Vol 54,490
Day's Range N/A - N/A
Shares Out 3.19M
Stochastic %K 59%
Beta 1.72
Analysts Strong Buy
Price Target $8.00

Company Profile

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 930 2529
Fax: 972 8 930 2531
Address:
Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus, Jerusalem, Israel
Richard_Roma
Richard_Roma Jan. 28 at 5:16 PM
$SCNI $MRNO $XHLD Scni is a dumpster fire
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 27 at 10:18 PM
I can see $SCNI jet set like $MRNO tonight
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 27 at 9:36 PM
Can’t wait to see $SCNI double like $MRNO $XHLD I am in long SCNI !
0 · Reply
SadyK189
SadyK189 Jan. 27 at 3:03 AM
Top Stocks to watch tomorrow 2 / 2: $ADAG $GUTS $DRMA $SCNI $SONM ADAG:Looking good on daily chart. Key support at 1.80 - 2.05. Next key level to test is 3- 3.30. Currently at 2.46 GUTS: Good close of 4hours candle. 1.85 - 2.05 is acting acting as key support zone. Next key level to test is 3.1 - 3.35. Currently at 2.60 DRMA: Getting up on 4hours chart. Key support at 2.3 - 2.55. It can test 3.8 - 4.1 zone again. Currently at 3.07 SCNI is moving slowly and steadily but nicely on 4hours chart. Key support at 0.87 - 0.92. Next key level to test is 1.4 - 1.55. Currently at 1.12 SONM: Looking good on daily chart. Key support at 6.4 - 6.8. Next key level to test is 8.45 - 8.75. Currently at 7.68
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 26 at 11:21 PM
$SCNI LONG — Can be huge tomorrow — can run like $MBAI $SLGB
0 · Reply
Ditchg
Ditchg Jan. 26 at 10:12 PM
$SCNI pump and dumb or Info we don’t know about yet?
1 · Reply
Ultra_Calls
Ultra_Calls Jan. 26 at 3:43 PM
$SCNI Value play under $1. SCNI could be the next big low float runner and can run just like $BATL BATL hit $6.89 high today from being $1.30 stock!
1 · Reply
luckysupernova
luckysupernova Jan. 24 at 9:57 PM
$SCNI still undervalued.
1 · Reply
Bulltrader988
Bulltrader988 Jan. 24 at 9:42 PM
$SCNI Getting found 👃👀 https://x.com/i/status/2015147452278657275
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 6:37 AM
$SCNI
0 · Reply
Latest News on SCNI
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Jan 7, 2026, 7:00 AM EST - 27 days ago

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

Dec 2, 2025, 8:50 AM EST - 2 months ago

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Oct 6, 2025, 7:30 AM EDT - 4 months ago

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jul 29, 2025, 7:15 AM EDT - 6 months ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 12, 2025, 8:00 AM EDT - 8 months ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Jun 5, 2025, 9:00 AM EDT - 8 months ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025, 7:00 AM EDT - 8 months ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Announces Annual Financial Results for 2024

May 7, 2025, 4:01 PM EDT - 9 months ago

Scinai Announces Annual Financial Results for 2024

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

May 1, 2025, 7:00 AM EDT - 9 months ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 27, 2025, 9:25 AM EDT - 11 months ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 17, 2025, 7:00 AM EDT - 11 months ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Mar 5, 2025, 7:30 AM EST - 11 months ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Jan 6, 2025, 7:31 AM EST - 1 year ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 16, 2024, 9:25 AM EST - 1 year ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Sep 9, 2024, 11:12 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 29, 2024, 6:31 AM EDT - 1 year ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 2:28 PM EDT - 1 year ago

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 20, 2024, 9:30 AM EDT - 1 year ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 12:31 PM EDT - 1 year ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 8, 2024, 8:14 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 3, 2024, 9:32 AM EDT - 1 year ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:12 AM EDT - 1 year ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Jun 7, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 24, 2024, 4:01 PM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

May 6, 2024, 9:21 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Scinai leadership to attend BIO-Europe Spring 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Scinai leadership to attend BIO-Europe Spring 2024

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 29, 2024, 8:45 AM EST - 2 years ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Feb 13, 2024, 7:00 AM EST - 2 years ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Jan 25, 2024, 10:26 AM EST - 2 years ago

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Jan 4, 2024, 4:01 PM EST - 2 years ago

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Jan 4, 2024, 6:15 AM EST - 2 years ago

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Dec 29, 2023, 9:21 AM EST - 2 years ago

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Dec 27, 2023, 7:15 AM EST - 2 years ago

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Dec 12, 2023, 7:26 AM EST - 2 years ago

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Dec 11, 2023, 8:11 AM EST - 2 years ago

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Richard_Roma
Richard_Roma Jan. 28 at 5:16 PM
$SCNI $MRNO $XHLD Scni is a dumpster fire
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 27 at 10:18 PM
I can see $SCNI jet set like $MRNO tonight
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 27 at 9:36 PM
Can’t wait to see $SCNI double like $MRNO $XHLD I am in long SCNI !
0 · Reply
SadyK189
SadyK189 Jan. 27 at 3:03 AM
Top Stocks to watch tomorrow 2 / 2: $ADAG $GUTS $DRMA $SCNI $SONM ADAG:Looking good on daily chart. Key support at 1.80 - 2.05. Next key level to test is 3- 3.30. Currently at 2.46 GUTS: Good close of 4hours candle. 1.85 - 2.05 is acting acting as key support zone. Next key level to test is 3.1 - 3.35. Currently at 2.60 DRMA: Getting up on 4hours chart. Key support at 2.3 - 2.55. It can test 3.8 - 4.1 zone again. Currently at 3.07 SCNI is moving slowly and steadily but nicely on 4hours chart. Key support at 0.87 - 0.92. Next key level to test is 1.4 - 1.55. Currently at 1.12 SONM: Looking good on daily chart. Key support at 6.4 - 6.8. Next key level to test is 8.45 - 8.75. Currently at 7.68
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 26 at 11:21 PM
$SCNI LONG — Can be huge tomorrow — can run like $MBAI $SLGB
0 · Reply
Ditchg
Ditchg Jan. 26 at 10:12 PM
$SCNI pump and dumb or Info we don’t know about yet?
1 · Reply
Ultra_Calls
Ultra_Calls Jan. 26 at 3:43 PM
$SCNI Value play under $1. SCNI could be the next big low float runner and can run just like $BATL BATL hit $6.89 high today from being $1.30 stock!
1 · Reply
luckysupernova
luckysupernova Jan. 24 at 9:57 PM
$SCNI still undervalued.
1 · Reply
Bulltrader988
Bulltrader988 Jan. 24 at 9:42 PM
$SCNI Getting found 👃👀 https://x.com/i/status/2015147452278657275
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 6:37 AM
$SCNI
0 · Reply
Richard_Roma
Richard_Roma Jan. 23 at 8:19 PM
$SCNI this company is hot garbage. Suspect it's being manipulated upward to avoid yet another delisting notice being under $1.
0 · Reply
TruthTooPower
TruthTooPower Jan. 23 at 7:15 PM
$SCNI!!! I'm telling You!!!!!!! We Are On The Verge Of Exploding!!! YES YES MARK IT!!!!!!
0 · Reply
Sjpu
Sjpu Jan. 23 at 5:44 PM
$SCNI likely diluting
0 · Reply
TruthTooPower
TruthTooPower Jan. 23 at 5:36 PM
$INDP!!! $LASE!!! $SCNI !!! “THE LIST”
1 · Reply
Ultra_Calls
Ultra_Calls Jan. 23 at 3:39 PM
$SCNI .93c // Can easily run 200% like $MOVE
0 · Reply
Ultra_Calls
Ultra_Calls Jan. 23 at 3:31 PM
Watching $SCNI very closely here. I bought a small starter. Looks like it can explode like $MOVE & $DRCT The float of SCNI is only like 800K+ So any catalyst will make this thing go absolutely crazy.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 19 at 8:49 PM
$SCNI RSI: 63.35, MACD: -0.0259 Vol: 0.07, MA20: 0.78, MA50: 0.93 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Dieseld28
Dieseld28 Jan. 16 at 10:58 PM
$IVF $SCNI
0 · Reply
TruthTooPower
TruthTooPower Jan. 16 at 5:33 PM
$INDP $SCNI !!! $INDP !!! $ENSC !!! $FRSX !!! $VERO !!! “The List” “Swing of the Year” Make Sure You Get Your Fair Share!!!
0 · Reply
topstockalerts
topstockalerts Jan. 16 at 1:56 PM
Pre Market Top Gainers PT2 $SVRE $JAGX $TNMG $PTLE $SCNI
0 · Reply
Bulltrader988
Bulltrader988 Jan. 15 at 7:54 PM
$SCNI Next monday 👃👀
1 · Reply
TruthTooPower
TruthTooPower Jan. 15 at 4:40 PM
$GV!!! $SCNI !!! $INDP !!! $ENSC !!! $FRSX !!! “The List” Make Sure You Get Your Fair Share!!!
0 · Reply